Expertise in
15
conditions

Dr. Theresa Werner

Hematology
85 N Medical Dr, 
Salt Lake City, UT 
Accepting New Patients
Offers Telehealth
Expertise in
15
conditions
85 N Medical Dr, 
Salt Lake City, UT 

Overview

Theresa Werner is a Hematologist practicing medicine in Salt Lake City, Utah.

Dr. Werner is highly rated in 15 conditions, according to our data. Her clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Virilizing Ovarian Tumor, and Ovarian Carcinosarcoma.

Dr. Werner is board certified in American Board Of Internal Medicine. She is actively involved in clinical research, co-authoring 73 peer reviewed articles and participating in 16 clinical trials. Dr. Werner is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in UT

Board Certifications

American Board Of Internal Medicine

Hospital Affiliations

University Of Utah Hospital And Clinics

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BridgeSpan
  • EPO
  • HMO
Cambia Health Solutions
  • EPO
  • INSURANCE PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Deseret Mutual Benefit Administrators
  • INSURANCE PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
  • PPO
EMI Health
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Regence
  • EPO
  • PPO
SelectHealth
  • HMO
  • POS
Steward Health Care
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Utah Health
  • EPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

Hematology-oncology - Nielsen Rehabilitation Hospital
85 N Medical Dr, Salt Lake City, UT 84112
Other Locations
Huntsman Cancer Institute, Hematology-oncology
1950 Circle Of Hope Dr, Salt Lake City, UT 84112

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

16 Clinical Trials

Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Procedure, Drug
Study Drug: Tazemetostat
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2026
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
A Randomized Phase 2 Study of Cabozantinib in Combination With Nivolumab in Advanced, Recurrent Metastatic Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: June 02, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cabozantinib S-malate, Nivolumab
Study Phase: Phase 2
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Procedure, Drug, Other
Study Drugs: Cediranib, Cediranib Maleate, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan, Topotecan Hydrochloride
Study Phase: Phase 2/Phase 3
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
A Phase 1/2 Trial of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase 1) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase 2) After Prior Platinum Containing First-Line Chemotherapy
Enrollment Status: Active_not_recruiting
Publish Date: April 29, 2026
Intervention Type: Other, Drug
Study Drugs: Topotecan Hydrochloride, Veliparib
Study Phase: Phase 1/Phase 2
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Assessment of Carboplatin Clearance Predictors: A PK Study on NCI-Sponsored Clinical Trials or Standard of Care Treatments Using Carboplatin
Enrollment Status: Active_not_recruiting
Publish Date: March 27, 2026
Intervention Type: Drug, Procedure
Study Phase: Phase 1
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients With Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Enrollment Status: Active_not_recruiting
Publish Date: March 24, 2026
Intervention Type: Drug, Procedure
Study Drugs: Carboplatin, Letrozole, Paclitaxel
Study Phase: Phase 3
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
A Phase II Study of Abemaciclib in Combination With Letrozole in Advanced, Recurrent or Metastatic Endometroid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: March 09, 2026
Intervention Type: Drug
Study Drugs: Abemaciclib, Letrozole
Study Phase: Phase 2
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: January 13, 2026
Intervention Type: Biological
Study Drug: Dostarlimab
Study Phase: Phase 1
View 9 Less Clinical Trials

73 Total Publications

Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.
Benchmarking the Current Landscape: Insights From an Association of American Cancer Institutes Survey on Academic Cancer Service Lines.
Journal: JCO oncology practice
Published: September 24, 2025
Similar Doctors
Expertise in
16
conditions
Expertise in
16
conditions
Referral may be required

Huntsman Cancer Institute, Univ. Of Utah

2000 Cir of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-3229
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Narendranath Epperla is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Epperla is highly rated in 16 conditions, according to our data. His clinical expertise encompasses Non-Hodgkin Lymphoma, B-Cell Lymphoma, Mantle Cell Lymphoma (MCL), Bone Marrow Aspiration, and Bone Marrow Transplant. Dr. Epperla is board certified in American Board Of Internal Medicine. Dr. Epperla is currently accepting new patients.

Expertise in
21
conditions
Dr. Josef Prchal
Hematology
Expertise in
21
conditions
Dr. Josef Prchal
Hematology
Referral may be required

University Of Utah Hospital Pathology Department

50 N Medical Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-581-2507
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Josef Prchal is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Prchal is highly rated in 21 conditions, according to our data. His clinical expertise encompasses Polycythemia Vera, Essential Thrombocythemia, Myelofibrosis, Myeloproliferative Neoplasms (MPN), and Bone Marrow Transplant. Dr. Prchal is board certified in American Board Of Internal Medicine. Dr. Prchal is currently accepting new patients.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Huntsman Cancer Institute Bmt

1950 Circle Of Hope Dr, 
Salt Lake City, UT 
 (0.1 miles away)
801-585-2626
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Douglas Sborov is a Hematologist practicing medicine in Salt Lake City, Utah. Dr. Sborov is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Multiple Myeloma, Relapsed Refractory Multiple Myeloma (RRMM), Smoldering Multiple Myeloma, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Sborov is board certified in American Board Of Internal Medicine. Dr. Sborov is currently accepting new patients.

Frequently Asked Questions about Dr. Theresa Werner

How do I make an appointment with Dr. Theresa Werner?

You can book an appointment with Dr. Theresa Werner by calling their office at 801-585-0100. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Theresa Werner a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Theresa Werner is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Theresa Werner specialize in?

While Dr. Theresa Werner is a Hematology, they have specific expertise in Ovarian Cancer, Endometrial Cancer, and Virilizing Ovarian Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Theresa Werner participate in research or clinical trials?

Yes. Dr. Theresa Werner has published 73 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Dr. Theresa Werner's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Theresa Werner accept my insurance?

Dr. Theresa Werner accepts most major insurance plans, including Aetna and Anthem BCBS. We recommend calling the office directly at 801-585-0100 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Werner's expertise for a condition
ConditionClose
View All 7 Advanced Conditions
View All 29 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile